Research Article
Volume 7 Issue 3 - 2020
Association of PAI-1 rs2227631 Variant and Clinical Factors with Recurrent Myocardial Infarction in Patients with Coronary Artery Disease
Vacis Tatarunas1*, Nora Kupstyte-Kristapone1,2,3, Ieva Eitminaviciute1, Remigijus Zaliunas2 and Vaiva Lesauskaite1
1Institute of Cardiology of Lithuanian University of Health Sciences, Kaunas, Lithuania
2Department of Cardiology of Lithuanian University of Health Sciences, Kaunas, Lithuania
3Cardiovascular Center of Republican Hospital of Siauliai, Siauliai, Lithuania
*Corresponding Author: Vacis Tatarunas, Institute of Cardiology of Lithuanian University of Health Sciences, Kaunas, Lithuania.
Received: December 26, 2019; Published: February 13, 2020


Background: There is a lack of studies explicating the association between genetic and clinical factors (such as diabetes mellitus) and increased risk of recurrent myocardial infarction (reMI). In this study, the impact of PAI-1 rs2227631 variant and clinical factors on reMI was analyzed in patients hospitalized due to acute coronary syndromes.

Methods and Results: All patients (n = 674) were hospitalized for percutaneous coronary intervention and stent implantation due to acute coronary syndromes (myocardial infarction or unstable angina). A total of 29.7% of the patients were hospitalized with recurrent MI, which was documented in anamnesis. Genotyping of PAI-1 rs2227631 was performed for all study patients. Diabetes and PAI-1 A allele were more frequently found in those patients with reMI who were older than 65 years. Multivariate binary regression analysis revealed that male gender, diabetes and A allele of PAI-1 rs2227631 increased the odds of reMI infarction by 1.764, 1.708 and 3.373 times, respectively. 

Conclusion: Multivariate analysis showed that in aged patients with acute coronary syndromes, the incidence of reMI increased in males, in patients with diabetes and in PAI-1 rs2227631 A allele carriers.

Keywords: Diabetes Mellitus; Recurrent MI; PAI-1 rs2227631


  1. Sanchis-Gomar F., et al. “Epidemiology of coronary heart disease and acute coronary syndrome”. Annals of Translational Medicine 4.13 (2016): 256.
  2. Townsend N., et al. “Cardiovascular disease in Europe -epidemiological update 2015”. European Heart Journal 36.40 (2015): 2696-2705.
  3. Mendis S., et al. “World Health Organization definition of myocardial infarction: 2008-09 revision”. International Journal of Epidemiology 40.1 (2011): 139-146.
  4. Motivala AA., et al. “A prior myocardial infarction: how does it affect management and outcomes in recurrent acute coronary syndromes?”. Clinical Cardiology 31.12 (2008): 590-596.
  5. Bui QT., et al. “Previous myocardial infarction as a risk factor for in-hospital cardiovascular outcomes (from the National Registry of Myocardial Infarction 4 and 5)”. The American Journal of Cardiology 111.12 (2013): 1694-1700.
  6. Jernberg T., et al. “Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective”. European Heart Journal 36.19 (2015): 1163-1170.
  7. Benyamini Y., et al. “Recovery of self-rated health as a predictor of recurrent ischemic events after first myocardial infarction: a 13-year follow-up”. Health Psychology Journal 33.4 (2014): 317-325.
  8. Szepietowska B., et al. “Insulin resistance predicts the risk for recurrent coronary events in post-infarction patients”. Cardiology Journal 22.5 (2015): 519-526.
  9. World Health Organization Media Centre. Fact Sheets - Diabetes (2013). 
  10. Mansfield MW., et al. “Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus”. Thrombosis and Haemostasis 74.3 (1995): 842-847.
  11. Cesari M., et al. “Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions”. Cardiovascular Therapeutics 28.5 (2010): e72-e91.
  12. Parpugga TK., et al. “The Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction”. Disease Markers 2015 (2015): 260101.
  13. Michelson AD. “Platelets”. 3rd Edition. San Diego, Calif, USA: Academic Press (2013).
  14. Mehta R., Shapiro AD. “Plasminogen activator inhibitor type 1 deficiency”. Haemophilia 14.6 (2008): 1255-1260.
  15. Cesari M., et al. “Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions”. Cardiovascular Therapeutics 28.5 (2010): e72-91. 
  16. Abboud N., et al. “Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study”. Genetic Testing and Molecular Biomarkers 14.1 (2010): 23-27.
  17. Liu Y., et al. “The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: A systematic review and meta-analysis involving 149,908 subjects”. Gene 673 (2018): 167-173.
  18. Thygesen K., et al. “Fourth Universal Definition of Myocardial Infarction”. Journal of the American College of Cardiology 72.18 (2018): 2231-2264.
  19. Hurst RT and Lee RW. “Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management”. Annals of Internal Medicine 139.10 (2003): 824-834.
  20. Corriere M., et al. “Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health burden”. Current Diabetes Reports 13.6 (2013): 805-813.
  21. Vlek AL., et al. “Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients”. Journal of Human Hypertension 22.5 (2008): 358-365.
  22. Rizzo MR., et al. “Elevated plasma activator inhibitor 1 is not related to insulin resistance and to gene polymorphism in healthy centenarians”. Atherosclerosis 160.2 (2002): 385-390.
  23. Jin C., et al. “Longitudinal Change in Fasting Blood Glucose and Myocardial Infarction Risk in a Population Without Diabetes”. Diabetes Care 40.11 (2017): 1565-1572.
  24. Tunaru S., et al. “20-HETE promotes glucose-stimulated insulin secretion in an autocrine manner through FFAR1”. Nature Communications 9.1 (2018): 177.
  25. Li X., et al. “20-Hydroxyeicosatetraenoic acid impairs endothelial insulin signaling by inducing phosphorylation of the insulin receptor substrate-1 at Ser616”. PLoS One 9.4 (2014): e95841.
  26. Williams JM., et al. “20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension”. Journal of Cardiovascular Pharmacology 56.4 (2010): 336-344.
  27. Su S., et al. “Plasminogen activator inhibitor-1 gene: selection of tagging single nucleotide polymorphisms and association with coronary heart disease”. Arteriosclerosis, Thrombosis, and Vascular Biology 26.4 (2006): 948-954.
  28. Morange PE., et al. “Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study”. Arteriosclerosis, Thrombosis, and Vascular Biology 27.10 (2007): 2250-2257.
  29. Koch W., et al. “4G/5G polymorphism and haplotypes of SERPINE1 in atherosclerotic diseases of coronary arteries”. Thrombosis and Haemostasis 103.6 (2010): 1170-1180.
  30. Ozolina A., et al. “Polymorphisms on PAI-1 and ACE genes in association with fibrinolytic bleeding after on-pump cardiac surgery”. BMC Anesthesiology 15 (2015): 122.
  31. Silander K., et al. “Gender differences in genetic risk profiles for cardiovascular disease”. PLoS One 3.10 (2008): e3615.
  32. Bentov Y., et al. “Polymorphic variation of genes in the fibrinolytic system and the risk of ovarian cancer”. PLoS One 4.6 (2009): e5918.
  33. García-González IJ., et al. “The -844 G>A PAI-1 polymorphism is associated with acute coronary syndrome in Mexican population”. Disease Markers (2015): 460974.
  34. Kim H., et al. “Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral head”. BMC Musculoskeletal Disorders 12 (2011): 160.
  35. Jie Huang., et al. “Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation”. Blood 120.24 (2012): 4873-4881.
  36. Yamamoto K., et al. “Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly”. Cardiovascular Research 66 (2005): 276-285.
  37. McMillin S and Ryan A. “Plasminogen Activator Inhibitor-1, Body Fat and Insulin Action in Aging Women”. Annals of gerontology and geriatric research 1.2 (2014): 1006.
  38. Testa R., et al. “The Pro/Pro genotype of the p53 codon 72 polymorphism modulates PAI-1 plasma levels in ageing”. Mechanisms of Ageing and Development 130.8 (2009): 497-500.
Citation: Vacis Tatarunas., et al. “Association of PAI-1 rs2227631 Variant and Clinical Factors with Recurrent Myocardial Infarction in Patients with Coronary Artery Disease”. EC Cardiology 7.3 (2020): 01-08.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

December Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 21, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.